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Introduction: The diagnosis of acute myocardial infarction (AMI) is based on an increase in
plasma troponin levels above the 99th percentile of a healthy reference population values. On
admission, over 30% of patients with AMI do not have specific symptoms and up to 70% of
them may have normal or non-diagnostic ECG recordings. In these patient subgroups cardiac
troponin assays may play a critical role in diagnosing AMI. Several diagnostic kits with
enhanced analytic sensitivity (high-sensitivity kits) have been developed recently.
Aim of study: To compare diagnostic sensitivity of troponin I (cTnI) and high-sensitivity troponin
T (hs-cTnT) in the diagnosis of acute myocardial infarction in patients with chest pain.
Type of study: Prospective, observational.
Patients and methods: We evaluated prospectively 107 consecutive patients [median (inter-
quartile range) age: 64 (55–75) years; 29 women] admitted to intensive cardiac care unit for
chest pain, with admission cTnI levelso0.1 mg/l. In all patients, the parameters determined on
admission included their levels of cTnI (chemiluminiscence immunoassay with microparticles,
Abbott, Architect i2000 analyzer), hs-cTnT (electrochemiluminiscence immunoassay; Roche
Cobas e411 analyzer), and myoglobin (immunoturbidimetry). The diagnosis of AMI was
established by the attending cardiologist (using the ‘‘universal’’ definition of acute myocardial
infarction). The cTnI and hs-cTnT cut-off values for AMI were 0.033 mg/l and 14 ng/l,
respectively. Troponin I levels were again determined at 6 and 12 h after admission.
Results: A total of 50 patients (46.7%) were diagnosed to have AMI with ST-segment elevation
(STEMI), 35 patients (32.7%) developed AMI without STE (non-STEMI), 10 patients (9.3%)
experienced a Type 2 AMI, four patients (3.7%) had unstable angina, and eight patients (7.5%)
chest pain of non-coronary etiology (most often vertebrogenic pain). The diagnostic sensitivity
of admission cTnI and hs-cTnT levels for AMI was 72% and 78%, respectively (p¼0.1814). The
correlation between cTnI and hs-cTnT was 0.67 (po0.001; Spearman rank correlation coeffi-
cient). The diagnostic sensitivity of admission hs-cTnT and cTnI in STEMI patients was 82% vs.
70%, respectively (p¼0.0771). In non-STEMI patients, similar baseline cTnI and hs-cTnT
diagnostic sensitivity was found, 74.3% and 71.4%, respectively (p¼0.91).ch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
. Hroma´dka).
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c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 2 7 – e 2 3 1e228Conclusion: Patients with STEMI showed a trend toward a baseline diagnostic sensitivity of
hs-cTnT superior to that of cTnI. In non-STEMI patients, the sensitivity of admission cTnI and
hs-cTnTwas similar.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.Table 1 – Basic characteristics of the study population.
n (%)
Men 78 (73)
DM 31 (29)
Arterial hypertension 88 (82)
Smoking status 63 (59)
Dyslipidemia 90 (84)
Previous CHD 26 (24)
eGFRo1 ml/s 32 (30)
Age (yrs) 64.0 [54.5–75.0]
eGFR (ml/s) 1.15 [0.93–1.39]
DM — diabetes mellitus; CHD — coronary heart disease; eGFR —
estimated glomerular filtration rate according to the four para-
meter MDRD equation (Modification of Diet in Renal Disease).1. Introduction and aim
Troponins are proteins of a tropomyosin complex of striate
muscle myocytes involved in muscle contractility. The tropo-
nin complex consists of three specific proteins, troponin C
(calcium-binding unit), troponin T (tropomyosin-binding sub-
unit), and troponin I (subunit binding actin, thereby inhibiting
contraction). The troponin C in cardiomyocytes and skeletal
muscle is identical. As troponins T and I in the above tissues
show different antigenic properties, those present in the
myocardium are referred as ‘‘cardiac’’ (cTn); these troponins
are currently the most important laboratory markers in the
diagnosis of acute myocardial infarction (AMI) [1–3]. Novel
highly sensitive troponin assays have refuted the assumption
that troponins are released into blood only in pathological
situations. Measurable levels can be found even in absolutely
healthy individuals, a finding reflecting the physiological
regeneration of cardiomyocytes (approx. 1% of cardiomyocytes
succumb to apoptosis each year). As a result, any cTn detected
in blood originates in the myocardium (100% organ specificity);
but the boundaries discriminating reversible from irreversible
alterations (necrosis) in the myocardium have not been clearly
identified yet [4,5]. Advances in the analytical potential of
assays determining cTn levels are progressively shifting the
clinical perception of cTn measurement results from qualita-
tive scales of simply ‘‘positive/negative’’ toward fully quanti-
tative determination allowing for earlier diagnosis of AMI and
opening space for a potential role of cTn in establishing
prognosis in a variety of diseases. From the perspective of
clinical practice, a diagnostic dilemma is particularly obvious
in patients with chest pain and unspecific ECG changes
(30–40% of AMI patients do not have symptoms on admission,
and normal or non-diagnostic ECG recordings may be present
in up to 70% of patients) [6]. In these patients, we often have to
wait until results of cardiospecific laboratory investigations
become available. The analytical sensitivity of standard cTn
kits does allow to detect a demonstrable increase in cTn levels
after 3–4 h since the onset of coronary ischemia [7]. This may
lead to later initiation of treatment of acute coronary syn-
drome in the decision-making algorithm. High-sensitivity cTn
assays eliminate this drawback due to earlier evidence of
myocardial necrosis and identification of even minor lesions
[7]. Another important consideration is their ability to distin-
guish between unstable angina and AMI without ST-segment
elevation (non-STEMI), an area where a high degree of sensi-
tivity may be important in establishing the correct diagnosis.
The aim of our pilot study was to compare the diagnostic
sensitivity and specificity of troponin I (cTnI) and high-
sensitivity troponin T (hs-cTnT) in the differential diagnosis
of chest pain in patients admitted to an intensive cardiac
care unit.2. Patients and methods
A total of 107 consecutive patients (for more detailed char-
acteristics of patients—see Table 1), admitted to our intensive
cardiac care unit between 8/2010 and 8/2011 for chest pain
and with cTnI levels o0.1 mg/l on admission, were included
into our study. The limit was based on the assumption that
high-sensitivity assays should best demonstrate their super-
iority at low cTn levels. The time between onset of chest pain
and admission sampling was r4 h in 71 (66%) patients, 44 h
and r8 h in 17 (16%) patients, 48 h and r12 in 8 (7%)
patients and 412 h in 11 (10%) patients. The parameters
measured on admission in all patients included cTnI (chemi-
luminiscence immunoassay on microparticles, Abbott Archi-
tect i2000 analyzer) and myoglobin (immunoturbidimetry;
Beckman-Coulter, AU 5400 analyzer); hs-cTnT (electrochemi-
luminiscent immunoassay; Roche Cobas e411 analyzer) has
been determined retrospectively. After o1 h following the
collection, the sample was stored at 2–8 1C for o8 h and then
frozen at 80 1C until analysis. Analysis was performed
batch-wise o10 months after collection. The stability of
sample suggested by manufacturer is 24 h at 28 1C and 12
months at 20 1C. The time course of troponin I levels were
determined from blood samples collected on 3 occasions (on
admission, and 6 and 12 h later). High-sensitivity cTnT was
measured only in blood samples obtained on admission. The
cut-off values of cardiac troponins for AMI were set at the
99th percentile of the reference population (using data of kit
manufacturers), with both manufacturers declaring a o10%
coefficient of variation. As a result, the cut-off values for cTnI
and hs-cTnI were 0.033 mg/l and 14 ng/l, respectively. The
myoglobin cut-off value for AMI in our study was the upper
reference limit (using data of the kit manufacturer) of 92 mg/l
(men) and 76 mg/l (women).
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Statistical analysis was performed using MS Excell 2010 and R
2.1.2.0 software (http://r-project.org/). Descriptive statistics
is presented as a median (inter-quartile range), unless
otherwise stated. Correlation was calculated using a non-
parametric method (Spearmann coefficient of correlation);
differences between 2 groups were determined using the
Wilcoxon sign rank test and effects on cardiac troponins by
various factors were tested using multiple regression analy
sis. Statistical significance of differences between the diag
nostic sensitivity of cardiac troponins was calculated using
the McNemar’s chi-square test according to a published
procedure [8].
The diagnosis of AMI was established by the attending
cardiologist. To diagnose AMI in patients with chest pain, the
physician used the modified universal definition of MI [1]
according to the following algorithm: Detection of an increase in troponin I with at least one
value above the 99th percentile of the reference popula-
tion within 24 h of the complaints onset. At the same time, evidence of ischemia by at least one of
the following findings: new changes in the ST segment,
newly developed LBBB, development of pathological Q
waves, or new wall motion abnormality as assessed by
an imaging technique).In patients with evidence of AMI, ECG curves were used to
distinguish AMI with and without STE from Type 2 AMI, with
the latter due to increased oxygen consumption or decreased
oxygen supply in the presence of a coronary spasm, embo-
lization into a coronary artery, in anemia, hypotension, or
hypertension.Table 2 – Diagnostic sensitivity of cTnI and hs-cTnT wit
admission). Figures in parentheses show numbers of po
Diagnosis (n) cTnI hs-cTnT
non-STEMI (35) 74.3% (26) 71.4% (2
STEMI (50) 70% (35) 82% (41
Type-2 AMI (10) 70% (7) 80% (8)
Total AMI (95) 71.6% (68) 77.9% (7
Unstable angina (4) 25% (1) 50% (2)
AMI— acute myocardial infarction, non-STEMI— AMI without ST
sensitivity troponin T.
Table 3 – Diagnostic specificity of individual tests (blood
individual specificities show numbers of negative result
cTnI hs-cTnT
No AMI (n¼12) 75% (9) 50% (6)
AMI — acute myocardial infarction, cTnI — troponin I, hs-cTnT —4. Results
Acute myocardial infarction was diagnosed in a total of 95
patients (89%). Details specifying causes of chest pain and
diagnostic sensitivity of the respective markers are shown in
Table 2. All patients with STEMI had a revascularization
procedure, 49 patients underwent primary percutaneous
coronary intervention (PCI: the proportion of interventions
on right coronary artery [RCA], ramus circumflexus [RC] and
left coronary artery [LAD] were 45%, 8% and 47% respectively)
and one patient was scheduled for coronary artery bypass
grafting (CABG). In the group of non-STEMI patients, a
revascularization procedure was performed in 32 individuals
(30 had PCI: the proportion of interventions on RCA, RC and
LAD were 35%, 24% and 41% respectively, 2 patients were
scheduled for CABG, 2 patients were treated conservatively, 1
patient was not scheduled for coronary angiography). On
admission, hs-cTnT and cTnI levels were 24.2 (14.1–34.2) ng/l
and 0.05 (0.02–0.08) mg/l, respectively.
Admission hs-cTnT in patients with non-STEMI had a diag-
nostic sensitivity similar to that of cTnI. A statistically and
clinically significant correlation of 0.67 was found between the
measured values of both cardiac troponins (po0.001; Spearman
rank correlation coefficient). Using a multiple regression model
(hs-cTnT levels as a dependent variable; diabetes mellitus,
dyslipidemia, hypertension, smoking status, history of coronary
artery disease (CAD), sex, interval between the onset of com-
plaints and admission to hospital, and estimated glomerular
filtration rate using the MDRD equation as independent vari-
ables), we found that the admission levels of hs-cTnT are
significantly determined by the presence of dyslipidemia
(p¼0.019; 95% CI for beta¼2.7–26.8) and a history of CHD at
the limit of statistical significance (p¼0.05). Using an analogical
model, cTnI levels were significantly affected also by a history
of CHD (p¼0.033) and smoking status at the limit of statistical
significance (p¼0.091).h individual diagnoses (blood sampling on
sitive results (above the cut-off values).
p (hs-cTnT vs. cTnI) Myoglobin
5) 0.92 71.4% (25)
) 0.0771 72% (36)
– 80% (8)
4) 0.1814 72.6% (69)
– 0% (0)
E, STEMI— AMI with STE, cTnI— troponin I, hs-cTnT— high-
sampling on admission). Figures in brackets with
s (below the cut-off value).
p (hs-cTnT vs. cTnI) Myoglobin
0.2482 50% (6)
high-sensitivity troponin T.
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pain was due to unstable angina, and 8 individuals with chest
pain of non-ischemic etiology. While aware of the low
informative value of our findings, we used our data to derive
the specificities of individual tests (Table 3).
Further, we compared the discrepancies in baseline posi-
tivity and negativity of hs-cTnT and cTnI. High-sensitivity
troponin Twas positive, in contrast with admission negative
value of troponin I, in 12% of patients (n¼13), of whom 10
had AMI, the finding in 1 patient was assessed as unstable
angina, and chest pain in 2 patients was assessed as of non-
coronary etiology. In 4% of baseline TnI positive patients
(n¼4), admission value of hs-cTnTwas negative (3 non-STEMI
patients and 1 STEMI patient).5. Discussion
Diagnostic sensitivity of high-sensitivity troponins for the
diagnosis of AMI might be superior to that of myoglobin and
‘‘standard’’ troponins as early as on admission [9,11]. In our
study, we found that the sensitivity of hs-cTnT in STEMI
patients was higher by 12% as compared with cTnI. However,
in patients where cTn assay is critical for the diagnosis, (i.e.,
in non-STEMI patients), the sensitivity of admission cTnI
and hs-cTnT levels was similar. This might be due to the
usually longer interval between the onset of chest pain and
baseline laboratory investigations in our non-STEMI patients,
when the sensitivity of cTnI and hs-cTnT may be already
comparable.
It should be noted that the terms ‘‘standard’’, ‘‘sensitive’’,
and ‘‘highly sensitive’’ have been used inconsistently and
reflect the advances in analytical sensitivity and accuracy of
assays. This could possibly also explain the comparable
sensitivity of both assays observed in our non-STEMI
patients. The cTnI assay (chemiluminiscence assay on micro-
particles, Abbott Architect i2000 analyzer, Abbott) belongs to
the ‘‘sensitive’’ generation and the diagnostic efficacy of this
assay has been reported by some authors to be comparable
with the ‘‘highly sensitive’’ ones [10,12].
A limitation of our study is its highly selected study
population with a very low proportion of diagnoses other
than AMI. As a result, our data were not large enough to
reliably calculate the diagnostic specificity, which was lower
for hs-cTnT as compared with cTnI. On the other hand, it is
most desirable for the prevalence (pretest probability) of AMI
in the study population to be as high as possible [13], a
requirement met in our study. It can be assumed that a
decreasing prevalence of AMI in a study population is
associated with a decrease in diagnostic specificity, i.e., an
increasing proportion of false positive results. At the same
time, there is growing evidence that any increase in cTn
levels (even below the cut-off value for AMI) is associated
with a worsening of prognosis [14]. The question thus arises
whether the higher numbers of false positive results (using
current criteria) in hs-cTnTare due to an inherent error of the
assay or, rather, contributes to improving care of the patient.
The recent guidelines of the European Society of Cardiology
(ESC) for the management of non-STEMI patients [15] have
incorporated hypersensitive cTn assays into the diagnosticalgorithm because of their ability of earlier detection in AMI
patients. In the case of an ambiguous clinical picture, it is
recommended to perform a control assay 3 h later, when its
sensitivity for AMI diagnosis is close to 100%. The Czech
guidelines for myocardial revascularization procedures [16]
have not included high-sensitivity troponin assays into the
diagnostic algorithm yet. In our retrospective study, we
focused on diagnostic properties of hs-cTnTat patient admis-
sion. That is why we could not (unfortunately) determine
concentrations of hs-cTnT after 3–6 h after admission due to
missing samples at these times. Specific universal algorithms
(timing and frequency of blood sampling for cTn) adjusted to
the needs of high-sensitivity troponin assays beyond a stage
of local experience have not been established. Decreasing the
cut-off value for AMI, a process necessarily associated with
the increasingly widespread use of high-sensitivity troponins
thus — quite paradoxically — places higher demands on the
evidence-based decision-making of the physician, whether or
not they will indicate a cTn assay and the way they will
interpret its results. The ultimate consideration in diagnosing
AMI continues to be clinical suspicion only then followed by
confirmation using cTn (and not in reverse order) [17].6. Conclusion
The baseline diagnostic sensitivity for acute myocardial
infarction of hs-cTnT is superior to that of cTnI, particularly
in STEMI patients. In patients with non-STEMI, the baseline
sensitivity of cTnI and hs-cTnT was similar. Further studies
are needed to better evaluate the role of hs-cTnT in patients
with acute chest pain.Acknowledgment
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